Adrian Towse : Citation Profile


Are you Adrian Towse?

Office of Health Economics

6

H index

1

i10 index

112

Citations

RESEARCH PRODUCTION:

16

Articles

46

Papers

13

Books

RESEARCH ACTIVITY:

   24 years (1994 - 2018). See details.
   Cites by year: 4
   Journals where Adrian Towse has often published
   Relations with other researchers
   Recent citing documents: 27.    Total self citations: 20 (15.15 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pto443
   Updated: 2018-09-22    RAS profile: 2018-04-23    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Hampson, Grace (9)

Berdud, Mikel (4)

Garau, Martina (4)

Cole, Amanda (3)

Shah, Koonal (2)

Danzon, Patricia (2)

Cubi-Molla, Patricia (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Adrian Towse.

Is cited by:

Cole, Amanda (4)

Garau, Martina (3)

Devlin, Nancy (2)

Culyer, Anthony (2)

Hampson, Grace (2)

Pertile, Paolo (2)

Shah, Koonal (2)

O'Neill, Phill (2)

Forster, Martin (2)

Claxton, Karl (1)

Garcia-Alonso, Maria (1)

Cites to:

Danzon, Patricia (8)

Shah, Koonal (6)

Szymanski, Stefan (5)

Garau, Martina (5)

Valletti, Tommaso (5)

Philipson, Tomas (5)

Rice, Nigel (5)

Claxton, Karl (5)

Lakdawalla, Darius (4)

Jena, Anupam (4)

DiMasi, Joseph (3)

Main data


Where Adrian Towse has published?


Journals with more than one article published# docs
Health Economics5
The European Journal of Health Economics4
Health Policy2
International Journal of the Economics of Business2
PharmacoEconomics2

Working Papers Series with more than one paper published# docs
Briefings / Office of Health Economics14
Consulting Reports / Office of Health Economics13
Research Papers / Office of Health Economics10
Occasional Papers / Office of Health Economics6

Recent works citing Adrian Towse (2018 and 2017)


YearTitle of citing document
2018MANAGING DERIVED DEMAND FOR ANTIBIOTICS IN ANIMAL AGRICULTURE. (2018). Hennessy, David A. In: 2018 Annual Meeting, August 5-7, Washington, D.C.. RePEc:ags:aaea18:274359.

Full description at Econpapers || Download paper

2018Excess Prices for Drugs in Medicare: Diagnosis and Prescription. (2018). Zeckhauser, Richard ; Frank, Richard G. In: Working Paper Series. RePEc:ecl:harjfk:rwp18-005.

Full description at Econpapers || Download paper

2017A review of international coverage and pricing strategies for personalized medicine and orphan drugs. (2017). Degtiar, Irina. In: Health Policy. RePEc:eee:hepoli:v:121:y:2017:i:12:p:1240-1248.

Full description at Econpapers || Download paper

2017Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. (2017). Gourzoulidis, George ; Maniadakis, Nikolaos ; Parissis, John ; Giamouzis, Gregory ; Stafylas, Panagiotis ; Kourlaba, Georgia . In: Health Policy. RePEc:eee:hepoli:v:121:y:2017:i:4:p:363-377.

Full description at Econpapers || Download paper

2017The bare necessities? A realist review of necessity argumentations used in health care coverage decisions. (2017). Kleinhout-Vliek, Tineke ; Boer, Bert ; de Bont, Antoinette . In: Health Policy. RePEc:eee:hepoli:v:121:y:2017:i:7:p:731-744.

Full description at Econpapers || Download paper

2018Funding breakthrough therapies: A systematic review and recommendation. (2018). Hanna, E ; Auquier, P ; Badora, K ; Dabbous, O ; Borissov, B ; Dussart, C ; Toumi, M. In: Health Policy. RePEc:eee:hepoli:v:122:y:2018:i:3:p:217-229.

Full description at Econpapers || Download paper

2018Integrating social justice concerns into economic evaluation for healthcare and public health: A systematic review. (2018). Dukhanin, Vadim ; Merritt, Maria W ; Taylor, Holly A ; Dowdy, David W ; Zwerling, Alice ; Searle, Alexandra. In: Social Science & Medicine. RePEc:eee:socmed:v:198:y:2018:i:c:p:27-35.

Full description at Econpapers || Download paper

2018Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands. (2018). , Ellen ; Negro, Simona O ; Schellen, Frank ; Fischer, Piret Kukk. In: Technological Forecasting and Social Change. RePEc:eee:tefoso:v:128:y:2018:i:c:p:133-143.

Full description at Econpapers || Download paper

2017Active Ingredients: Exploring the Key Factors Affecting the Rising Cost of Developing New Drugs. (2017). Wunnava, Phanindra ; Fossett, Sarah J. In: IZA Discussion Papers. RePEc:iza:izadps:dp10817.

Full description at Econpapers || Download paper

2017Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study. (2017). Garau, Martina ; Garrison, L ; Towse, T ; Hernandez-Villafuerte, K. In: Consulting Reports. RePEc:ohe:conrep:001781.

Full description at Econpapers || Download paper

2018The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries. (2018). Cole, Amanda ; Towse, A ; Zamora, B. In: Consulting Reports. RePEc:ohe:conrep:002009.

Full description at Econpapers || Download paper

2018A Critique of the Paper The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List. (2018). Towse, A ; Shaw, B ; Hernandez-Villafuerte, K. In: Consulting Reports. RePEc:ohe:conrep:002015.

Full description at Econpapers || Download paper

2018Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. (2018). Cole, Amanda ; Sullivan, R ; Lorgelly, P ; Towse, A. In: Research Papers. RePEc:ohe:respap:002030.

Full description at Econpapers || Download paper

2017Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval. (2017). Chambers, James D ; Neumann, Peter J ; Kamal-Bahl, Sachin J ; Subedi, Prasun ; Salem, Mark ; Wilkinson, Colby L ; Thorat, Teja . In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0291-9.

Full description at Econpapers || Download paper

2017EQ-5D and the EuroQol Group: Past, Present and Future. (2017). Devlin, Nancy J ; Brooks, Richard . In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-017-0310-5.

Full description at Econpapers || Download paper

2017How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. (2017). Vogler, Sabine ; Dedet, Guillaume ; Pedersen, Hanne Bak ; Schneider, Peter ; Joncheere, Kees ; Wirtz, Veronika J ; Ferrario, Alessandra ; Paris, Valerie . In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:15:y:2017:i:3:d:10.1007_s40258-016-0300-z.

Full description at Econpapers || Download paper

2017A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?. (2017). Hampson, Grace ; Cole, Amanda ; Devlin, Nancy ; Marsden, Grace ; Cowles, Emma . In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:15:y:2017:i:4:d:10.1007_s40258-017-0309-y.

Full description at Econpapers || Download paper

2018Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching. (2018). Husereau, Don ; Selya-Hammer, Carl ; Feagan, Brian. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:16:y:2018:i:3:d:10.1007_s40258-018-0371-0.

Full description at Econpapers || Download paper

2017Pareto-improving income redistribution: expanding consumer access to the vaccines market. (2017). Garcia-del-Barrio, Pedro. In: Economics of Governance. RePEc:spr:ecogov:v:18:y:2017:i:3:d:10.1007_s10101-017-0190-z.

Full description at Econpapers || Download paper

2018Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. (2018). Angelis, Aris ; Kanavos, Panos ; Lange, Ansgar . In: The European Journal of Health Economics. RePEc:spr:eujhec:v:19:y:2018:i:1:d:10.1007_s10198-017-0871-0.

Full description at Econpapers || Download paper

2018The impact of copayments on mental healthcare utilization: a natural experiment. (2018). Lambregts, Timo R. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:19:y:2018:i:6:d:10.1007_s10198-017-0921-7.

Full description at Econpapers || Download paper

2017Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. (2017). Ijzerman, Maarten J ; Krahn, Murray ; Fenwick, Elisabeth ; Koffijberg, Hendrik . In: PharmacoEconomics. RePEc:spr:pharme:v:35:y:2017:i:7:d:10.1007_s40273-017-0509-1.

Full description at Econpapers || Download paper

2018Cost-Effectiveness Thresholds: the Past, the Present and the Future. (2018). Thokala, Praveen ; Tong, Thaison ; Leech, Ashley A ; Ochalek, Jessica. In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:5:d:10.1007_s40273-017-0606-1.

Full description at Econpapers || Download paper

2017Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey. (2017). Chen, Gang ; Maxwell, Aimee ; Iezzi, Angelo ; Richardson, Jeff . In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:1:y:2017:i:1:d:10.1007_s41669-016-0002-3.

Full description at Econpapers || Download paper

2017Can Price Transparency Contribute to More Affordable Patient Access to Medicines?. (2017). Vogler, Sabine ; Paterson, Kenneth R. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:1:y:2017:i:3:d:10.1007_s41669-017-0028-1.

Full description at Econpapers || Download paper

2018Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends. (2018). Piatkiewicz, Trevor Jozef ; Holm-Larsen, Tove ; Traulsen, Janine Marie. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0044-1.

Full description at Econpapers || Download paper

2018Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). (2018). Hampson, Grace ; Garau, Martina ; Profico, Antonio ; Mazzanti, Nicola Amedeo ; Devlin, Nancy. In: PharmacoEconomics - Open. RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0048-x.

Full description at Econpapers || Download paper

Works by Adrian Towse:


YearTitleTypeCited
2017Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation In: Health Policy.
[Full Text][Citation analysis]
article1
1999Is disease management relevant in Europe: some evidence from the United Kingdom In: Health Policy.
[Full Text][Citation analysis]
article0
2011Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement In: NBER Working Papers.
[Full Text][Citation analysis]
paper4
2015Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement.(2015) In: Health Economics.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 4
article
2012Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context In: NBER Working Papers.
[Full Text][Citation analysis]
paper7
2015Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context.(2015) In: Health Economics.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 7
article
2014What is the Role of HTA for Biosimilars? In: Briefings.
[Full Text][Citation analysis]
paper0
2008The Market for Biosimilars: Evolution and Policy Options In: Briefings.
[Full Text][Citation analysis]
paper5
2006Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds In: Briefings.
[Full Text][Citation analysis]
paper0
1997Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry In: Briefings.
[Full Text][Citation analysis]
paper2
1998From Efficacy to Cost-Effectiveness In: Briefings.
[Full Text][Citation analysis]
paper0
2003Reducing Harm to Patients in the National Health Service. Will the Governments Compensation Proposals Help? In: Briefings.
[Full Text][Citation analysis]
paper1
2016How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? In: Briefings.
[Full Text][Citation analysis]
paper0
2017Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefings.
[Full Text][Citation analysis]
paper0
2017How can HTA meet the needs of health system and government decision makers? In: Briefings.
[Full Text][Citation analysis]
paper0
2017Transferability of HTA In: Briefings.
[Full Text][Citation analysis]
paper0
2017HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers? In: Briefings.
[Full Text][Citation analysis]
paper0
2017Incentives for New Drugs to Tackle Anti-Microbial Resistance In: Briefings.
[Full Text][Citation analysis]
paper0
2017Additional Elements of Value for Health Technology Assessment Decisions In: Briefings.
[Full Text][Citation analysis]
paper0
2017Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help? In: Briefings.
[Full Text][Citation analysis]
paper0
2014The Expanding Value Footprint of Oncology Treatments In: Consulting Reports.
[Full Text][Citation analysis]
paper2
2011The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2010Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2009Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2006Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2015Data Governance Arrangements for Real-World Evidence In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2016Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making In: Consulting Reports.
[Citation analysis]
paper1
2016Four Case Studies to Explore the Added Value of Oxford AHSN In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2016Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Policy Options for Formulary Development in Middle-income Countries In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2017Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2018Review of CRAs Report Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2018Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2012The R&D Cost of a New Medicine In: Monographs.
[Full Text][Citation analysis]
book6
2011New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options In: Monographs.
[Full Text][Citation analysis]
book0
2010Biosimilars: How Much Entry and Price Competition Will Result? In: Monographs.
[Full Text][Citation analysis]
book0
2008The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way In: Monographs.
[Full Text][Citation analysis]
book0
2006Economic Post-Launch Studies: Matching the Desirable with the Feasible In: Monographs.
[Full Text][Citation analysis]
book1
1995Financing Health Care in the UK: A Discussion of NERAs Prototype Model to Replace the NHS In: Monographs.
[Full Text][Citation analysis]
book1
1995Industrial Policy and the Pharmaceutical Industry In: Monographs.
[Full Text][Citation analysis]
book0
1995Value of the Pharmaceutical Industry to the UK Economy In: Monographs.
[Full Text][Citation analysis]
book0
1997Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada? In: Monographs.
[Full Text][Citation analysis]
book1
1999Disease Management, the NHS and the Pharmaceutical Industry In: Monographs.
[Full Text][Citation analysis]
book0
2002Cost-Effectiveness Thresholds: Economic and ethical issues In: Monographs.
[Full Text][Citation analysis]
book14
2002Influencing Prescribing in a Primary Care Led NHS In: Monographs.
[Full Text][Citation analysis]
book0
2002Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty In: Monographs.
[Full Text][Citation analysis]
book3
2013Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold In: Occasional Papers.
[Full Text][Citation analysis]
paper5
2012The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation? In: Occasional Papers.
[Full Text][Citation analysis]
paper2
2011Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Papers.
[Full Text][Citation analysis]
paper1
2010New Drugs to Tackle Antimicrobial Resistance: EU Policy Options In: Occasional Papers.
[Full Text][Citation analysis]
paper1
2014Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies? In: Occasional Papers.
[Full Text][Citation analysis]
paper0
2015International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa In: Occasional Papers.
[Full Text][Citation analysis]
paper0
2013Exploring the link between health and wealth in decision making In: Research Papers.
[Full Text][Citation analysis]
paper0
2012Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Papers.
[Full Text][Citation analysis]
paper2
2011Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches In: Research Papers.
[Full Text][Citation analysis]
paper0
2011Incentives for R&D for New Antimicrobial Drugs In: Research Papers.
[Full Text][Citation analysis]
paper0
2011Incentives for R&D for New Antimicrobial Drugs.(2011) In: International Journal of the Economics of Business.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 0
article
2010Using QALYs in Cancer: Review of the Methodological Limitations In: Research Papers.
[Full Text][Citation analysis]
paper8
2016Uncertainty and Risk in HTA Decision Making In: Research Papers.
[Full Text][Citation analysis]
paper0
2017Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value In: Research Papers.
[Full Text][Citation analysis]
paper1
2017Macro Evaluation of the NIHR Oxford Biomedical Research Centre In: Research Papers.
[Full Text][Citation analysis]
paper0
2018Real World Evidence for Coverage Decisions: Opportunities and Challenges In: Research Papers.
[Full Text][Citation analysis]
paper0
2018Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions In: Research Papers.
[Full Text][Citation analysis]
paper0
2015Multi-indication Pricing: Pros, Cons and Applicability to the UK In: Seminar Briefings.
[Full Text][Citation analysis]
paper1
2016Fostering incentives for research, development, and delivery of interventions for neglected tropical diseases: lessons from malaria In: Oxford Review of Economic Policy.
[Full Text][Citation analysis]
article0
2012Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe? In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article9
2014Orphan drugs policies: a suitable case for treatment In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article7
2004Genetic screening, health care and the insurance industry In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article2
2006The desirability and feasibility of economic studies of drugs post-launch In: The European Journal of Health Economics.
[Full Text][Citation analysis]
article1
2013Operationalizing Value-Based Pricing of Medicines In: PharmacoEconomics.
[Full Text][Citation analysis]
article8
2016Biosimilars: How Can Payers Get Long-Term Savings? In: PharmacoEconomics.
[Full Text][Citation analysis]
article3
2015European Union Pharmaceutical Markets: A Case for Differential Pricing? In: International Journal of the Economics of Business.
[Full Text][Citation analysis]
article2
2007If it aint broke, dont price fix it: the OFT and the PPRS In: Health Economics.
[Full Text][Citation analysis]
article4
1994The Political Economy of Healthcare. By David Resisman. MacMillan Press, London, 1993. No. of pages: 267. ISBN: 0‐333‐58579‐8 In: Health Economics.
[Full Text][Citation analysis]
article0
1999Medical negligence and the NHS: an economic analysis In: Health Economics.
[Citation analysis]
article3

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated August, 2th 2018. Contact: CitEc Team